Trial
NCT04267393
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Nonalcoholic Steatohepatitis (NASH)
Intervention
BMS-986263
Why stopped
Trial terminated because of lack of efficacy in the short term acute phase.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-04